Skip to main content

USP to Host Veterinary Medicines Events in November 2012 in Rockville, MD

Type of Posting: General Announcement

Posting Date: 22–May–2012

The United States Pharmacopeia (USP) will be holding the first Veterinary Drugs Stakeholder Forum on November 9, 2012. The meeting will be held at USP’s Rockville, MD headquarters.

Immediately prior to the Veterinary Drugs Stakeholder Forum, USP will host the Solubility Criteria for Veterinary Products Workshop, which is cosponsored by the American Academy of Veterinary Pharmacology and Therapeutics. The workshop will be held on Wednesday and Thursday, November 7–8, 2012.

Stakeholder Forums are held to enable an exchange of information and perspectives, with the ultimate goal of improving USP standards and information. The Veterinary Drugs Stakeholder Forum provides an opportunity to educate stakeholders on USP activities, help USP staff understand veterinary drug issues, and discuss compendial issues and emerging USP initiatives that may affect veterinary drug stakeholders. All discussions are conducted in an open forum, with stakeholders from various organizations sharing their perspectives. The Stakeholder Forum can be attended in person or remotely through a simultaneous web-based component.

The objective of the workshop is to create a framework that will be used to evaluate solubility parameters for veterinary drugs. The USP Expert Panel for Veterinary Products is evaluating the relationship between the species-specific gastro-intestinal (GI) characteristics and the appropriate criteria for describing drug solubility in veterinary species. The industry recognizes that, given the diverse (GI) physiologies observed across veterinary species and the potential differences between the human and veterinary GI tracts, the currently employed human drug criteria for classifying drug solubility may not be universally applicable. The new USP general chapter will initially address solubility criteria in dogs and cattle and will expand to other animal species in future revisions.

For further information, please contact Jessica Simpson (